Patients with hematologic malignancies are increasingly admitted to the intensive care unit (ICU) when life-threatening events occur. We sought to report outcomes and prognostic factors in these patients.
INTRODUCTION
Cancer is a leading cause of death in North America and Europe. 1, 2 Hematologic malignancies account for 20% of cancer diagnoses, with about 900,000 patients diagnosed in 2008 worldwide, a number similar to that of patients with prostate cancer. 1, 2 Over the last two decades, patients with hematologic malignancies have benefitted considerably from therapeutic advances. [3] [4] [5] [6] [7] As a result, a growing number of people are living with active hematologic malignancies. 1, 7, 8 These patients are at risk for lifethreatening acute illness as a result of infection, 9 toxicity of intensive treatments 10, 11 and targeted therapies, 3, 12 and decompensation of comorbid conditions. 13 Reluctance to admit patients with hematologic malignancies and life-threatening acute events is eroding 14, 15 as evidence accumulates that outcomes are not influenced by a need for intensive care unit (ICU) admission 16 and that ICU mortality rates have declined significantly over the last two decades.
Outcomes in critically ill hematology patients have been assessed in several studies. However, most of these studies were either retrospective, 17,19-21 mixed patients with hematologic malignancies and solid tumors, or focused on specific complications such as acute respiratory failure, kidney injury, or septic shock. [21] [22] [23] Furthermore, most of these studies included patients admitted to the ICU up to 15 years ago 24 and therefore did not reflect recent improvements in the management of acute respiratory failure, 25, 26 kidney injury, 23 tumor lysis syndrome, 27,28 sepsis, 29 and septic shock. 19, 21 Also, the recent broadening of ICU admission policies for hematology patients, which helps explain the increased number of admitted patients 14, 15, 30, 31 and would result in earlier ICU admissions, 32 may have translated into changes in outcomes that need to be clarified. Mortality according to time in the ICU at initiation of life-supporting interventions 22 and mortality according to the number of days spent with a given lifesupporting intervention need to be assessed in a large cohort of patients managed in different ICUs. Finally, most studies reported ICU or hospital mortality rates 20, 22, 33, 34 but obtained no information on outcomes several months after ICU discharge, particularly regarding maintenance of cancer chemotherapy, disease control, and quality of life.
To address these issues with the goal of obtaining data for guiding therapeutic decisions, we performed a prospective, observational cohort study in 17 centers in France and Belgium. Only patients with hematologic malignancies managed in 2010 to 2011 were studied. In all 17 centers, patients were managed jointly by hematologists and intensivists. ICU patients received follow-up for 1 year after ICU discharge, with a telephone interview to assess health-related quality of life (HRQOL) and disease status.
PATIENTS AND METHODS
The study was approved by the appropriate ethics committees in France and Belgium. All patients or relatives were informed and consented to participate in the study. The study was carried out in 17 university or university-affiliated centers in France and Belgium that belonged to a research network instituted in 2005 . 25 In all 17 centers, a senior intensivist and a senior hematologist are available around the clock and make ICU-admission decisions together.
From January, 1, 2010, to May, 1, 2011, consecutive patients having hematologic malignancies who were admitted to the participating ICUs for any reason were included. Exclusion criteria were complete cure of the malignancy for more than 5 years, ICU admission only to maximize safety of a procedure, and age younger than 18 years. In each center, an investigator used a standardized electronic case-report form to collect the study data. Data were also collected on patients with hematologic malignancies who were refused ICU admission (Fig 1) . In each center, we reported the ICU refusal rate (number of patients considered for ICU admission but not admitted/number of patients admitted to the ICU throughout the study period).
Ninety days after ICU discharge, HRQOL was assessed by asking the patients to complete the short-form 36 questionnaire (SF-36) 35 ,36 during a telephone interview by a trained social worker. Results were compared with cancer patients who were not admitted to the ICU. 37 Six months after ICU discharge, the hematologists in charge of the patients were asked whether the ICU admission changed the patient's therapeutic intensity (compared with the standard optimal chemotherapy treatment protocol for the relevant disease, stage, and comorbidity profile) and disease status. Declined study participation (n = 21)
They were too well to benefit (n = 44)
Hospital survival (n = 39; 88.6%)
Admitted to the ICU (n = 1,032)
Not admitted to the ICU (n = 344; 25%)
They were too sick to benefit (n = 300)
Hospital survival (n = 78; 26%) The data in the tables and figures were collected prospectively. Newly diagnosed malignancies were defined as diagnosed within the past 4 weeks. The Sepsis-Related Organ Failure Assessment (SOFA) score was computed at admission then daily throughout the patient's stay in the ICU 38 ; this score provides an estimate of the risk of death based on organ dysfunction. The performance status 23 and Charlson comorbidity index were determined at ICU admission. 39 Both leukemia and lymphoma are already part of the Charlson index. Reasons for ICU admission were recorded based on the main symptoms at ICU admission. Acute respiratory failure was defined as oxygen saturation less than 90% or PaO 2 less than 60 mmHg on room air combined with severe dyspnea at rest with an inability to speak in sentences or a respiratory rate greater than 30 breaths per minute or clinical signs of respiratory distress. 25 Shock was defined as previously reported. 21 Life-supporting interventions, anti-infectious agents, prophylactic treatments, urate oxidase use, and diagnostic procedures were administered at the discretion of the attending intensivists, who followed best clinical practice and guidelines. Chemotherapy, corticosteroids, hematopoietic growth factors, immunosuppressive drugs, and other cancer-related treatments were prescribed by the hematologist in charge of each patient in accordance with institutional guidelines. Neutropenia was defined as a neutrophil count of less than 500/mm 3 . Etiologic diagnoses were made by consensus by the intensivists, hematologists, and consultants, according to recent definitions. 16, 23, 25 In particular, etiologies of pulmonary involvement were diagnosed based on predefined criteria 25 ; for possible or probable invasive pulmonary aspergillosis, the most recent definitions were used.
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The primary outcome was vital status at hospital discharge. Results are described as medians and interquartile ranges (IQR) for quantitative variables and numbers and percentages for qualitative variables. Univariable prognostic analyses were based on the Wilcoxon rank-sum test or the Fisher's exact test. To identify independent predictors of hospital mortality, characteristics available at ICU admission associated with P values less than .1 by univariate analysis or deemed clinically relevant were included in a multivariable logistic regression model with backward selection. Non-log-linear continuous variables were dichotomized. Missing data were completed by multiple imputation with chained equations. 41 Results are reported with and without imputation. Goodness-of-fit of the model was assessed using the Le Cessie-van Houwelingen test on all imputed datasets. 42 A secondary objective was to assess whether starting life-supporting interventions late during the ICU stay or using life-supporting interventions for prolonged periods was beneficial. The conditional survival probability associated with organ failure was estimated among patients requiring mechanical ventilation, vasoactive drugs, and/or renal replacement therapy (RRT) within 24 hours after ICU admission. It was computed for day X, as the percentage of patients alive at ICU discharge among patients alive after X days of organ failure. We also modeled the center effect using a logistic regression model with a random center effect on the intercept. Estimates were obtained using a maximum likelihood estimator (glmmML_0.82-1 R-package), and center effect has been tested using a permutation test as recommended by Lee and Braun.
All tests were two-sided, and P values less than .05 were considered significant. Analyses were done using R software version 2.14.2 (R Project for Statistical Computing, Wien, Austria). Figure 1 , 1,376 patients with hematologic malignancies were considered for ICU admission, of whom 1,032 patients (75%) were admitted to the ICU; 21 patients declined to participate, leaving 1,011 patients enrolled onto the study. ICU refusal rate was 0.25 (IQR, 0.22 to 0.27), ranging from 0.11 to 0.30.
RESULTS

As shown in
ICU admission occurred 4 days (IQR, 1 to 6) after hospital admission; 451 patients (44.6%) were admitted within 1 day, including 267 patients (26%) admitted directly to the ICU. The main reasons for ICU admission were acute respiratory failure and shock (62.5% and 42.3% patients, respectively). ICU refusal rate was not different in patients admitted from the hematologic wards compared with patients admitted from the emergency department.
As listed in Table 1 , non-Hodgkin's lymphoma, acute myeloid leukemia, and myeloma accounted for 71.3% of the total cohort. Median time since diagnosis of malignancy was 5.4 months (IQR, 0 to 33.5); 386 patients (38.2%) had newly diagnosed malignancies and 234 patients (23.1%) were in complete or partial remission. Only 27% †High risk for tumor lysis syndrome (bulky tumor, hyperleukocytic leukemia), arrhythmia, and bleeding. of patients had participated in studies of chemotherapy. Bone marrow or hematopoietic stem-cell transplantation (BMT/HSCT) was performed in 252 patients (24.9%); the transplantations were autologous in 107 patients and allogeneic in 145 patients. Neutropenia was present at ICU admission in 289 patients (28.6%) and developed in the ICU in 91 additional patients (9%).
Hospital mortality was 39.3%. Day-90 and 1-year mortality rates were 47.5% and 56.7%, respectively. By univariate analysis, variables associated with hospital mortality were age (18 to 50 years, 34%; 51 to 60 years, 35.3%; 61 to 70 years, 42.6%; and Ͼ 70 years, 45.8%; P ϭ .02), poor performance status (57.4% v 34.9%; P Ͻ .001), Charlson comorbidity index (median, 5; IQR, 3 to 6; v median, 3; IQR, 1 to 4; P ϭ .0001), remission of the malignancy (32.5% v 40.3%; P ϭ .02), allogeneic BMT/HSCT (52.4% v 38.3%; P ϭ .0002), and time from hospital to ICU admission less than 24 hours (33.9% v 43.7%; P ϭ .002). There was no significant association between the rate of ICU refusal and hospital mortality. Table 2 lists outcomes associated with the use of life-supporting interventions. The use of mechanical ventilation, vasoactive drugs, or RRT was associated with increased hospital mortality. Trends toward lower mortality rates were found in patients younger than 60 years, having a good performance status, or not having received allogeneic BMT/HSCT. However, mortality was significantly lower in patients who received no more than one life-supporting intervention. Figure 2 shows that hospital mortality increased with the number of days spent receiving both invasive mechanical ventilation and vasoactive drugs. Appendix Figure A1 (online-only) lists daily SOFA scores throughout the ICU stay indicating that the number of organ dysfunctions was significantly associated with mortality from day 1 onward. Importantly, neither time spent with any single life-supporting intervention nor time from ICU admission to initiation of a life-supporting intervention was associated with hospital mortality (Fig 3 and Appendix Figure A2 ). Table 3 lists the definite diagnoses and corresponding hospital mortality rates.
Patients admitted to the ICU within 1 day after hospital admission had SOFA scores on day 1 similar to those in patients admitted later but they also had lower incidences of life-supporting interventions (67.7% v 74.2%; P ϭ .04). Patients admitted within 24 hours had shorter times since malignancy diagnosis (median, 153 days; IQR, 0 to 1,230 days; v median, 173.5 days; IQR, 20 to 812 days; P ϭ .04) and were more likely to have good performance status (86.6% v 75.5%; P Ͻ .001). They were less likely to have their primary hematologists in the same hospital as the ICU (57.6% v 96.7%; P Ͻ .001), a history of allogeneic HSCT/BMT (11% v 17%; P ϭ .006), neutropenia (19.6% v 35.8%; P Ͻ .001), and treatment with antifungal agents (27% v 47%; P Ͻ .001) or antiviral agents (36% v 48%; P ϭ .0002) during the first 3 Daily assessment of the probability of hospital mortality according to the number of days spent receiving both invasive mechanical ventilation and vasoactive drugs. The y-axis on the left indicates hospital mortality rates with the corresponding curve (mean Ϯ standard deviation) and the y-axis on the right indicates the number of patients, with corresponding bars showing the number of patients who survived (gold) and the number of patients who died (blue).
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www.jco.org days in the ICU. Obtaining ICU admission required more than one call to the ICU physician in only 5.9% of patients admitted within 24 hours compared with 18% of patients admitted later (P Ͻ .001).
By multivariate analyses (Fig 4; Table 4 ), 10 variables were independently associated with hospital mortality. Mortality was lower in patients with complete or partial remission of the malignancy and in those patients admitted to the ICU within 24 hours after hospital admission. Other factors were associated with higher mortality: poor performance status (bedridden or completely disabled), higher Charlson comorbidity index, allogeneic BMT/HSCT, SOFA score on ICU admission, ICU admission after cardiac arrest or for acute respiratory failure, organ infiltration by the malignancy, and invasive aspergillosis. No significant center effect on mortality was found.
On day 90, 69.2% of the survivors who were eligible for telephone interviews (Appendix Fig A3) completed the short form 36 questionnaire. Among survivors, no differences could be found between patients responding to telephone interviews and those who could not be reached. Twenty per cent of patients perceived their physical and mental health as altered, with no significant differences compared to age-and gendermatched cancer patients who were not admitted to the ICU. After 6 months, the hematologists reported that all but seven ICU survivors were continuing their cancer treatment, that ICU admission did not influence therapeutic intensity in 80% of ICU survivors, and that 80% of ICU survivors were in complete or partial remission.
DISCUSSION
This work is the first large, prospective multicenter study of ICU and post-ICU outcomes in patients with hematologic malignancies only. In addition to mortality data, quality-of-life data were obtained after 3 months, and treatment intensity and disease status were assessed after 6 months. The 39.3% hospital mortality rate is encouraging, particularly as most patients had at least two organ dysfunctions, and up to 75% required mechanical ventilation, vasoactive drugs, or RRT. Other encouraging findings are the continued use of intensive cancer treatments after ICU discharge, the good quality of life in ICU survivors after 3 months, and the 80% disease-control rate after 6 months. Thus, ICU admission prolonged survival with good quality of life. ICU admission within 24 hours of hospital admission was identified as a variable significantly associated with better survival and possibly amenable to modification.
Previous studies included far fewer patients, 20,33,34 mixed patients with solid cancers and hematologic malignancies, 20,33,34 focused on specific complications, 21,23,25 and studied only ICU or hospital mortality without obtaining quality-of-life data. Consequently, their results are difficult to compare with ours. The 1,011 hematology patients in our study were consecutive patients who probably reflect the overall population of patients with hematologic malignancies and a need for ICU admission. Our hospital mortality rate is lower than in previous recent studies. 20, 33, 34 Older age is a known risk factor in hematology patients, 13 particularly those with critical illnesses, 43 and the comorbidity burden and performance status are also wellestablished prognostic factors.
13 Also in agreement with previous publications is our finding of higher mortality in bedridden patients 20,22,33,43 and in allogeneic BMT or HSCT recipients.
24,44-46
However, substantial survival rates can be achieved in select allogeneic BMT/HSCT recipients without uncontrolled graft-versus-host disease, 47 in whom mechanical ventilation is no longer futile.
24,44,48
Worse organ dysfunction scores, cardiac arrest, and invasive pulmonary aspergillosis were associated with hospital mortality in our cohort and in previous studies. 20, 23, 33, 43, 49, 50 The independent impact of acute respiratory failure on mortality indicates a need for developing better management strategies. 25 Recent advances in the understanding of organ infiltration by leukemia and lymphoma cells may help to improve survival.
27,51 Recent studies that report improved outcomes in critically ill hematology patients 18, 19, 21, 34 have led to broader ICU admission policies, the main selection criteria being good performance status and availability of potentially life-prolonging treatments. 14,15,30 Consent should be obtained from the patient, after a discussion of the disease status and range of treatment options. Abbreviation: ICU, intensive care unit.
52
‫ء‬
ICU admission for safer chemotherapy initiation was restricted to patients with high tumoral burden (hyperleukocytic leukemia or bulky lymphoma) who were at high risk for leukostasis, tumor lysis syndrome, or compression from bulk tumors. 
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In our cohort, we collected daily information on organ dysfunctions. Severity of organ dysfunctions is known to be a major prognostic factor. 19, 20, 30, 33, 53 However, our study contributes three new findings. First, use of a single life-supporting intervention was associated with good survival. For instance, among patients receiving mechanical ventilation but no vasoactive drugs or RRT, 67.6% were alive at hospital discharge (Table 2) ; this proportion was 77.5% for vasoactive drugs only and 81.3% for RRT only. Second, the time from ICU admission to initiation of life-supporting interventions did not influence survival. Third, longer time on lifesupporting interventions was not associated with worse survival. These last two findings indicate that current practices regarding patient selection for starting and continuing life-supporting interventions are appropriate.
Our finding that a shorter time from hospital to ICU admission was independently associated with better survival offers some hope that prompt ICU admission might improve survival. It suggests that immediate ICU admission of hematology patients with incipient organ dysfunction may be appropriate. In previous studies, early ICU management of acute respiratory failure decreased the rates of intubation 25 and septic shock 21 as well as improved outcomes of patients at high risk for tumor lysis syndrome and acute respiratory failure. 51, 54 However, the effect of early ICU admission on mortality is difficult to interpret. Patients admitted early had similar SOFA scores to those admitted later on; consequently, their earlier admission might reflect a more acute disease process compared with patients admitted later. It is striking however that a smaller proportion of early-admitted patients required more than one call to the intensivist (5.9% v 18% in patients admitted later), suggesting that late ICU admission may be due in some cases to reluctance to admit hematology patients, with lateradmitted patients being initially considered too sick to benefit from intensive care. Studies conducted jointly by intensivists and hematologists are needed to evaluate criteria for early ICU admission in terms of their ability to improve survival. Until they become available, our finding of better outcomes after earlier ICU admission supports a broad ICU admission policy with a trial of full-code therapy. Intermediate-care units located contiguous to the ICU could also be used for those patients at high risk for rapid deterioration. Rapid response teams should also be evaluated in this very specific patient population.
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This study has several limitations. First, all the study centers had hematologists and intensivists available around the clock, a situation not encountered in all hospitals. Second, the study was performed in France and Belgium and may not be relevant to other countries. However, in this study and a previous study by our group, 25 the results were within the ranges reported in other European countries, 16 North America, 17,24,45 and Brazil. 23,33 Third, 9.6% of the patients were lost to follow-up during the 1-year study period, and the day-90 telephone interview was conducted in 69% of eligible patients. Finally, in this multicenter study, no rigid criteria have been used to make the decision to send patients to ICUs across the different participating centers. However, ICU refusal rate was not significantly different across centers and was not associated with mortality. Moreover, there was no center effect on hospital mortality.
In summary, the 39.3% hospital mortality rate in our study supports the usefulness of ICU admission of select critically ill patients with hematologic malignancies. The good cancer control and good-to-excellent HRQOL in ICU survivors constitute further evidence that ICU resources are being used to good effect in this population. The better survival in patients admitted more rapidly to the ICU invites studies evaluating the effects on outcomes of earlier ICU admission.
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